Ganitumab

Generic Name: AMG 479
Study IDStudied Indication or DiseasePhaseStudy TitleSynopsis
20050118Advanced solid tumors1A Phase 1, Open-Label, Dose Finding Study Evaluating the Safety and Pharmacokinetics of AMG 479 in Subjects with Advanced Solid Tumors
20060134Advanced solid tumors1bA Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of AMG 479 with Biologics or Chemotherapy in Adult Subjects with Advanced Solid Tumors
20060283Relapsed or Refractory Ewing’s Family Tumors and Desmoplastic Small Round Cell2A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing’s Family Tumors and Desmoplastic Small Round Cell Tumors
20060362Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer2An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 with Exemestane or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer
20060534Previously Untreated Extensive Stage Small Cell Lung Cancer (SCLC)1b/2A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-line Treatment for Extensive Stage Small Cell Lung Cancer
20060540Metastatic adenocarcinoma of the pancreas3A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Metastatic Adenocarcinoma of the Pancreas
20080257First-line advanced squamous Non-Small Cell Lung Cancer (NSCLC)1b/2A Phase 1b/2 Study of AMG 479 in Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
20080261Locally advanced adenocarcinoma of the pancreas2A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Locally Advanced Unresectable Adenocarcinoma of the Pancreas